학술논문


EBSCO Discovery Service
발행년
-
(예 : 2010-2015)
전자자료 공정이용 안내

우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.

공정이용 지침
  • 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
  • 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
  • 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
  • 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
  • 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
  • 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
  • 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
  • 상업적·영리적 목적으로 자료를 전송·복제·활용
  • ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
  • EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
  • 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
  • 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
  • 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문' 에서 검색결과 30건 | 목록 1~20
Academic Journal
Chan JR; Global PKPD and Pharmacometrics, Eli Lilly and Company, Indianapolis, IN, 46285, USA. jrchan@lilly.com.; Allen R; Worldwide Research, Development and Medical, Pfizer Inc. Kendall Square, Cambridge, MA, 02139, USA.; Boras B; Worldwide Research, Development and Medical, Pfizer Inc.,, La Jolla, CA, 92121, USA.; Cabal A; Eisai Inc., NJ, Nutley, USA.; Damian V; GlaxoSmithKline, Collegeville, PA, 19426, USA.; Gibbons FD; Takeda, Cambridge, MA, 02139, USA.; Gulati A; Merck & Co. Inc., Rahway, NJ, USA.; Hosseini I; Genentech Inc., South San Francisco, CA, 94080, USA.; Kearns JD; Novartis Institutes for BioMedical Research, Cambridge, MA, 02139, USA.; Saito R; Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Japan.; Cucurull-Sanchez L; GlaxoSmithKline, Stevenage, Hertfordshire, UK.; Selimkhanov J; Takeda Development Center Americas Inc., San Diego, CA, 92121, USA.; Stein AM; Pharmacometrics, Novartis Institutes of BioMedical Research, Cambridge, MA, USA.; Umehara K; Roche Pharmaceutical Research and Early Development, Basel, Switzerland.; Wang G; Drug Metabolism and Pharmacokinetics, Vertex Pharmaceuticals, Abingdon, Oxfordshire, UK.; Wang W; Clinical Pharmacology and Pharmacometrics, Janssen Research and Development, LLC, Spring House, PA, 19477, USA.; Neves-Zaph S; Data and Data Science, Translational Disease Modeling, Sanofi, USA.
Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-8744 (Electronic) Linking ISSN: 1567567X NLM ISO Abbreviation: J Pharmacokinet Pharmacodyn Subsets: MEDLINE
Academic Journal
Mitra A; Clinical Pharmacology, Kura Oncology, Boston, Massachusetts, USA.; Ahmed MA; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Krishna R; Integrated Drug Development, Certara USA, Inc., Princeton, New Jersey, USA.; Sun K; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Gibbons FD; Quantitative Solutions, Preclinical and Translational Sciences, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Campagne O; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.; Rayad N; Clinical Pharmacology, Modeling and Simulation, Parexel International (MA) Corporation, Mississauga, Ontario, Canada.; Roman YM; Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, USA.; Albusaysi S; Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.; Burian M; Translational Medicine Neuroscience and Gene Therapy, UCB Biopharma SRL, Braine-l'Alleud, Belgium.; Younis IR; Clinical Pharmacology Sciences, Gilead Science, Inc, Foster City, California, USA.
Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE
Academic Journal
Shields JD; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Baker D; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Balazs AYS; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Bommakanti G; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Casella R; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Cao S; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Cook S; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Escobar RA; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Fawell S; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Gibbons FD; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Giblin KA; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Goldberg FW; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Gosselin E; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Grebe T; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Hariparsad N; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Hatoum-Mokdad H; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Howells R; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Hughes SJ; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Jackson A; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Karapa Reddy I; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Kettle JG; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Lamont GM; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Lamont S; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Li M; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Lill SON; Pharmaceutical Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden.; Mele DA; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Metrano AJ; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Mfuh AM; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Morrill LA; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Peng B; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Pflug A; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Proia TA; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Rezaei H; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Richards R; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Richter M; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Robbins KJ; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; San Martin M; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Schimpl M; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Schuller AG; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Sha L; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Shen M; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Sheppeck JE 2nd; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Singh M; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Stokes S; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Song K; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Sun Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Tang H; Discovery Sciences, R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Wagner DJ; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Wang J; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Wang Y; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Wilson DM; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K.; Wu A; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Wu C; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Wu D; Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Wu Y; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Xu K; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Yang Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Yao T; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Ye M; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Zhang AX; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Zhang H; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Zhai X; Discovery Sciences, R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Zhou Y; Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing 100176, P. R. China.; Ziegler RE; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.; Grimster NP; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Academic Journal
Singh D; CN Bio Innovations Limited, Cambridge, United Kingdom.; Deosarkar SP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.; Cadogan E; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Flemington V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Bray A; CN Bio Innovations Limited, Cambridge, United Kingdom.; Zhang J; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America.; Reiserer RS; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Schaffer DK; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Gerken GB; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Britt CM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Werner EM; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Gibbons FD; DMPK, Oncology R&D, AstraZeneca, Boston, Massachusetts, United States of America.; Kostrzewski T; CN Bio Innovations Limited, Cambridge, United Kingdom.; Chambers CE; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Davies EJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Montoya AR; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Fok JHL; Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Hughes D; CN Bio Innovations Limited, Cambridge, United Kingdom.; Fabre K; MPS Center of Excellence, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.; Wagoner MP; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.; Wikswo JP; Department of Physics and Astronomy and the Vanderbilt Institute for Integrative Biosystems Research and Education, Nashville, Tennessee, United States of America.; Departments of Biomedical Engineering and Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States of America.; Scott CW; Oncology Safety, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, United States of America.
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101183755 Publication Model: eCollection Cited Medium: Internet ISSN: 1545-7885 (Electronic) Linking ISSN: 15449173 NLM ISO Abbreviation: PLoS Biol Subsets: MEDLINE
Academic Journal
Tron AE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Belmonte MA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA.; Adam A; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Surface Oncology, Cambridge, MA, USA.; Aquila BM; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Alkermes, Inc., Waltham, MA, USA.; Boise LH; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.; Chiarparin E; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Cidado J; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Embrey KJ; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Gangl E; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Gibbons FD; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Gregory GP; School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, 3800, Australia.; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; Hargreaves D; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Hendricks JA; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Johannes JW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, VIC, 3000, Australia.; The Sir Peter MacCallum Center, Department of Oncology, University of Melbourne, Parkville, VIC, 3000, Australia.; Kazmirski SL; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Fulcrum Therapeutics, Cambridge, MA, USA.; Kettle JG; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Lamb ML; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Matulis SM; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.; Nooka AK; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, 30322, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, 30322, USA.; Packer MJ; Oncology, IMED Biotech Unit, AstraZeneca, Alderley Park, SK10 4TG, UK.; Peng B; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Rawlins PB; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Robbins DW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Nurix, Inc., San Francisco, CA, USA.; Schuller AG; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Su N; Discovery Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Yang W; Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Ye Q; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Zheng X; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Secrist JP; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; LifeMine Therapeutics, Cambridge, MA, USA.; Clark EA; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Wilson DM; Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, CB4 0WG, UK.; Fawell SE; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA.; Hird AW; Oncology, IMED Biotech Unit, AstraZeneca, Waltham, MA, 02451, USA. alexander.hird@astrazeneca.com.
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Academic Journal
Vasalou C; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.; Ferguson D; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.; Li W; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Muse V; Novo Nordisk Foundation Center for Protein Research, Copenhagen 2200, Denmark.; Gibbons FD; Biogen, Cambridge, Massachusetts 02142, United States.; Sonzini S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Zhang G; Dicerna Pharmaceuticals, Inc, Lexington, Massachusetts 02421, United States.; Pop-Damkov P; Takeda Pharmaceuticals, Cambridge, Massachusetts 02139, United States.; Gangl E; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.; Balachander SB; Bristol-Myers Squibb, Cambridge, Massachusetts 02142, United States.; Wen S; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.; Schuller AG; Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States.; Puri S; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Mazza M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Ashford M; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.; Fretland AJ; Repare Therapeutics, Cambridge, Massachusetts 02142, United States.; McGinnity DF; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.; Jones RDO; Oncology R&D, AstraZeneca, Cambridge CB4 0FZ, U.K.
Publisher: American Chemical Society Country of Publication: United States NLM ID: 101197791 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1543-8392 (Electronic) Linking ISSN: 15438384 NLM ISO Abbreviation: Mol Pharm Subsets: MEDLINE
Academic Journal
Flemington V; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom. vikki.flemington@astrazeneca.com.; Davies EJ; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Robinson D; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Sandin LC; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Delpuech O; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Zhang P; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Hanson L; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Farrington P; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Bell S; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Falenta K; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Gibbons FD; DMPK, Oncology, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom and Waltham, Massachusetts.; Lindsay N; DMPK, Oncology, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom and Waltham, Massachusetts.; Smith A; DMPK, Oncology, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom and Waltham, Massachusetts.; Wilson J; DMPK, Oncology, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom and Waltham, Massachusetts.; Roberts K; Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.; Tonge M; Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.; Hopcroft P; Discovery Science, BioPharmaceuticals R&D, AstraZeneca, Cambridge, England, United Kingdom.; Willis SE; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Roudier MP; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Rooney C; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Coker EA; Wellcome Sanger Institute, Cambridge, England, United Kingdom.; Jaaks P; Wellcome Sanger Institute, Cambridge, England, United Kingdom.; Garnett MJ; Wellcome Sanger Institute, Cambridge, England, United Kingdom.; Fawell SE; Oncology R&D, AstraZeneca, Waltham, England, United Kingdom.; Jones CD; Former employee of AstraZeneca.; Ward RA; Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.; Simpson I; Former employee of AstraZeneca.; Cosulich SC; Oncology R&D, AstraZeneca, Waltham, England, United Kingdom.; Pease JE; Oncology R&D, AstraZeneca, Waltham, England, United Kingdom.; Smith PD; Bioscience, Oncology R&D, AstraZeneca, Cambridge, England, United Kingdom.
Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Academic Journal
Patterson CM; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.; Balachander SB; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Grant I; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK.; Pop-Damkov P; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Kelly B; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.; McCoull W; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Parker J; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.; Giannis M; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.; Hill KJ; Pharmaceutical Technology and Development, Operations, AstraZeneca, Macclesfield, SK10 2NA, UK.; Gibbons FD; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Hennessy EJ; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Kemmitt P; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Harmer AR; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Gales S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Purbrick S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Redmond S; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Boston, MA, 02451, USA.; Skinner M; Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Graham L; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK.; Secrist JP; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Schuller AG; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Wen S; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Adam A; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Reimer C; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Cidado J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Wild M; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Gangl E; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Fawell SE; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Saeh J; Oncology R&D, AstraZeneca, Boston, MA, 02451, USA.; Davies BR; Oncology R&D, AstraZeneca, Cambridge, CB4 0FZ, UK.; Owen DJ; Starpharma, 4-6 Southampton Crescent, Abbotsford, VIC, 3067, Australia.; Ashford MB; Pharmaceutical Sciences, R&D, AstraZeneca, Macclesfield, SK10 2NA, UK. Marianne.Ashford@astrazeneca.com.
Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE
Academic Journal
Balachander SB; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Criscione SW; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Byth KF; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Cidado J; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Adam A; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Lewis P; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Macintyre T; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Wen S; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Lawson D; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Burke K; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Lubinski T; Translational Science, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Tyner JW; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Ashland, Oregon.; Kurtz SE; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Ashland, Oregon.; McWeeney SK; Division of Biostatistics, Department of Public Health and Preventive Medicine, Knight Cancer Institute, Oregon Health and Science University, Ashland, Oregon.; Varnes J; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Diebold RB; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Gero T; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Ioannidis S; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Hennessy EJ; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; McCoull W; Chemistry, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Saeh JC; Chemistry, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Tabatabai A; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Tavana O; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Su N; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts.; Schuller A; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Garnett MJ; Wellcome Sanger Institute, Hinxton, United Kingdom.; Jaaks P; Wellcome Sanger Institute, Hinxton, United Kingdom.; Coker EA; Wellcome Sanger Institute, Hinxton, United Kingdom.; Gregory GP; School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia.; Newbold A; Peter MacCallum Cancer Centre, Melbourne, Australia.; Johnstone RW; Peter MacCallum Cancer Centre, Melbourne, Australia.; Gangl E; DMPK, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Wild M; DMPK, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.; Zinda M; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Secrist JP; Bioscience, Oncology R&D, AstraZeneca, Boston, Massachusetts.; Davies BR; Projects, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Barry.Davies@astrazeneca.com Frank.Gibbons@astrazeneca.com.; Fawell SE; Early Oncology R&D, AstraZeneca, Boston, Massachusetts.; Gibbons FD; DMPK, Oncology R&D, AstraZeneca, Boston, Massachusetts. Barry.Davies@astrazeneca.com Frank.Gibbons@astrazeneca.com.
Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Academic Journal
Goliaei A; Drug Metabolism and Pharmacokinetics (DMPK), Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Novartis Institutes for Biomedical Research, Cambridge, Massachusetts, USA.; Woods HA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Tron AE; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Agios Pharmaceuticals, Cambridge, Massachusetts, USA.; Belmonte MA; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Secrist JP; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Ferguson D; Drug Metabolism and Pharmacokinetics (DMPK), Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Drew L; Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Fretland AJ; Drug Metabolism and Pharmacokinetics (DMPK), Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.; Aldridge BB; Department of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.; Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, USA.; Gibbons FD; Drug Metabolism and Pharmacokinetics (DMPK), Oncology R&D, AstraZeneca, Waltham, Massachusetts, USA.
Publisher: Wiley Country of Publication: United States NLM ID: 101580011 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2163-8306 (Electronic) Linking ISSN: 21638306 NLM ISO Abbreviation: CPT Pharmacometrics Syst Pharmacol Subsets: MEDLINE
Academic Journal
Beaver JE; Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.; Tasan MGibbons FDTian WHughes TRRoth FP
Publisher: Oxford University Press Country of Publication: England NLM ID: 9808944 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1367-4811 (Electronic) Linking ISSN: 13674803 NLM ISO Abbreviation: Bioinformatics Subsets: MEDLINE
Academic Journal
Ward RA; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Anderton MJ; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Bethel P; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; Breed J; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Cook C; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Davies EJ; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Dobson A; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; Dong Z; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China.; Fairley G; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Farrington P; Bioscience, Oncology R&D , AstraZeneca , Alderley Park, Macclesfield SK10 4TG , U.K.; Feron L; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Flemington V; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Gibbons FD; DMPK, Oncology R&D , AstraZeneca , Waltham , Massachusetts 02451 , United States.; Graham MA; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; Greenwood R; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Hanson L; Bioscience, Oncology R&D , AstraZeneca , Alderley Park, Macclesfield SK10 4TG , U.K.; Hopcroft P; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Howells R; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Hudson JJames MJones CDJones CRLi Y; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China.; Lamont S; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Lewis R; Medicinal Chemistry, Respiratory, Inflammation and Autoimmune (RIA), BioPharmaceuticals R&D , AstraZeneca , Gothenburg 431 50 , Sweden.; Lindsay N; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; McCabe J; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; McGuire T; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Rawlins P; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Roberts K; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Sandin LSimpson ISwallow S; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; Tang J; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China.; Tomkinson G; Chemical Development, Pharmaceutical Technology & Development , AstraZeneca , Macclesfield Campus, Macclesfield SK10 2NA , U.K.; Tonge M; Oncology and Discovery Sciences R&D , AstraZeneca , Darwin Building and Hodgkin Building, c/o Darwin Building, 310 Cambridge Science Park, Milton Rd , Cambridge CB4 0WG , U.K.; Wang Z; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China.; Zhai B; Pharmaron Beijing Co., Ltd. , 6 Taihe Road BDA , Beijing 100176 , P.R. China.
Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Academic Journal
Rual JF; Center for Cancer Systems Biology and Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA.; Venkatesan KHao THirozane-Kishikawa TDricot ALi NBerriz GFGibbons FDDreze MAyivi-Guedehoussou NKlitgord NSimon CBoxem MMilstein SRosenberg JGoldberg DSZhang LVWong SLFranklin GLi SAlbala JSLim JFraughton CLlamosas ECevik SBex CLamesch PSikorski RSVandenhaute JZoghbi HYSmolyar ABosak SSequerra RDoucette-Stamm LCusick MEHill DERoth FPVidal M
Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE
Academic Journal
Gabrielsson J; Swedish University of Agricultural Sciences, Department of Biomedical Sciences and Veterinary Public Health, Division of Pharmacology and Toxicology, Box 7028, SE-750 07 Uppsala, Sweden. Electronic address: johan.gabrielsson@slu.se.; Gibbons FD; DMPK Modeling & Simulation, Oncology IMED, AstraZeneca, Waltham, MA 02151, USA. Electronic address: Frank.Gibbons@astrazeneca.com.; Peletier LA; Mathematical Institute, Leiden University, PB 9512, 2300 RA Leiden, The Netherlands. Electronic address: peletier@math.leidenuniv.nl.
Publisher: Elsevier Science B.V Country of Publication: Netherlands NLM ID: 9317982 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0720 (Electronic) Linking ISSN: 09280987 NLM ISO Abbreviation: Eur J Pharm Sci Subsets: MEDLINE
Academic Journal
Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Academic Journal
Publisher: BioMed Central Ltd Country of Publication: England NLM ID: 100960660 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-760X (Electronic) Linking ISSN: 14747596 NLM ISO Abbreviation: Genome Biol Subsets: MEDLINE
검색 결과 제한하기
제한된 항목
[AR] Gibbons, Francis D
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어